Finless Foods develops cell-cultured and plant-based seafood alternatives with an initial focus on bluefin tuna. The company is constructing a Bay Area pilot facility to produce its first saleable cell-cultured bluefin tuna and is pursuing regulatory approval to enable sales and consumption. It plans to nationally launch its plant-based tuna into U.S. foodservice in 2022 and to explore international distribution in Asia while expanding its plant-based seafood portfolio. The company will use new funding to expand its team, deepen technical R&D, and build business capabilities to transition from R&D to a food company. Finless also aims to drive down the price of cell-cultured bluefin tuna to reach parity with conventional tuna and to reduce pressure on wild-capture tuna stocks. The company convenes an Impact Board of ocean and sustainable seafood experts and was the first to serve cell-cultured fish in the United States. Finless Foods, founded in 2017 by biochemists Michael Selden and Bryan Wyrwas, develops real fish meat grown from stem cells. The company uses cellular-agriculture technologies to grow marine-animal cells and is initially producing bluefin tuna. It aims to create more sustainable seafood without the environmental devastation or health hazards of traditional fishing and aquatic farming. Based in San Francisco, CA, Finless Foods raised $3.5M in seed funding. The company intends to use the funds to finalize its initial R&D phase and move into production, pending the closing of a Series A.

Total raised

$38M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2022